← All trials
NCT04037176
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Aug 31, 2020
- Completion date
- Feb 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Southern DenmarkLead sponsor
- University of Southern DenmarkStudy chair
- NovartisCollaborator
- University of Southern DenmarkStudy director
- University of Southern DenmarkSponsor investigator
- Thermo Fisher ScientificCollaborator
- University of Southern DenmarkOfficial
- University of Southern DenmarkOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.